$7.4 Billion Worldwide Non-Invasive Prenatal Testing

Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) — The “Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The global non-invasive prenatal testing market reached a value of US$ 2.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 7.4 Billion by 2027, exhibiting a CAGR of 16.9% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood.

The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.

The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advances in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself.

Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development.

Moreover, the shifting trend towards childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.

Key Questions Answered in This Report
1. What was the size of the global non-invasive prenatal testing market in 2021?
2. What is the expected growth rate of the global non-invasive prenatal testing market during 2022-2027?
3. What are the key factors driving the global non-invasive prenatal testing market?
4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?
5. What is the breakup of the global non-invasive prenatal testing market based on the product type?
6. What is the breakup of the global non-invasive prenatal testing market based on the test type?
7. What is the breakup of the global non-invasive prenatal testing market based on the technology?
8. What is the breakdown of the global non-invasive prenatal testing market based on the method?
9. What is the breakup of the global non-invasive prenatal testing market based on the application?
10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?
11. What are the key regions in the global non-invasive prenatal testing market?
12. Who are the key companies/players in the global non-invasive prenatal testing market?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Non-Invasive Prenatal Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakdown by Product Type
6.1 Consumables
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instruments
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Test Type
7.1 Maternity 21
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Harmony
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Panorama
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Verification
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 NIFTY
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast

8 Market Breakup by Technology
8.1 NGS
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 WGS
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Method
9.1 Ultrasound Detection
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Biochemical Screening Tests
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Cell-Free DNA in Maternal Plasma Tests
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Fetal Cells in Maternal Blood Tests
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Others
9.5.1 Market Trends
9.5.2 Market Forecast

10 Market Breakdown by Application
10.1 Trisomy
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Microdeletion Syndrome
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Others
10.3.1 Market Trends
10.3.2 Market Forecast

11 Market Breakup by End-User
11.1 Hospitals
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Diagnostic Laboratories
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Others
11.3.1 Market Trends
11.3.2 Market Forecast

12 Market Breakdown by Region

13 SWOT Analysis

14 Value Chain Analysis

15 Porters Five Forces Analysis

16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Agilent Technologies, Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Berry Genetics Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.3 BGI Genomics Co. Ltd.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.4 Eurofins Scientific Services Limited
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.5 F. Hoffmann-La Roche Ltd
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 SWOT Analysis
16.3.6 GE Healthcare
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.7 Genomix
16.3.7.1 Company. Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.8 Illumina Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Laboratory Corporation
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Natera Inc.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.11 Perkinelmer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Thermo Fisher Scientific Inc.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Yourgene Health plc
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials

For more information about this report visit https://www.researchandmarkets.com/r/2kg0gk

  • Global Non-Invasive Prenatal Testing Market


        

.